Biotest AG (BIOG_p.DE)
16 Feb 2018
* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG
* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)
FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.
* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST
* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017
* Biotest shares drop 12 percent to 7-month low (Adds share price, background)
FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.
* TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG